Increased striatal dopamine transporter density in moderately severe old restless legs syndrome patients

European Journal of Neurology

Volumn 19, Issue 9, 2012, Pages 1213-1218

  Kim, K W ^a,b   Jhoo, J H ^c   Lee, S B ^d   Lee, S D ^a   Kim, T H ^a   Kim, S E ^a   Kim, Y K ^a   Yoon, I Y ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Kangwon National University   (South Korea)

^d Dankook University   (South Korea)

Author keywords

D2 receptor; Dopamine; Dopamine transporter; Restless legs syndrome; Single photon emission computed tomography

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; IODINE 123;

AGED; ARTICLE; CLINICAL ARTICLE; COMPUTER PROGRAM; DISEASE ASSOCIATION; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; HUMAN; NEUROTRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUTAMEN; RESTLESS LEGS SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CAUDATE NUCLEUS; COCAINE; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IODOBENZENES; MALE; PUTAMEN; RADIOPHARMACEUTICALS; RECEPTORS, DOPAMINE D2; RESTLESS LEGS SYNDROME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84865285159     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03705.x     Document Type: Article

References (35)

1. Cho YW, Shin WC, Yun CH, et al. Epidemiology of restless legs syndrome in Korean adults. Sleep 2008; 31: 219-223.
2. Kim KW, Yoon IY, Chung S, et al. Prevalence, comorbidities and risk factors of restless legs syndrome in the Korean elderly population - results from the Korean Longitudinal Study on Health and Aging. J Sleep Res 2010; 19: 87-92.
3. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements during sleep with L-dopa: a double-blind, controlled study. Neurology 1988; 38: 1845-1848.
4. Wetter TC, Brunner J, Bronisch T. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry 2002; 35: 109-111.
5. Connor JR, Wang XS, Allen RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain 2009; 132: 2403-2412.
6. Nelson C, Erikson K, Pinero DJ, Beard JL. In vivo dopamine metabolism is altered in iron-deficient anemic rats. J Nutr 1997; 127: 2282-2288.
7. Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med 2009; 10: 123-128.
8. Michaud M, Soucy JP, Chabli A, Lavigne G, Montplaisir J. SPECT imaging of striatal pre- and postsynaptic dopaminergic status in restless legs syndrome with periodic leg movements in sleep. J Neurol 2002; 249: 164-170.
9. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000; 54: 502-504.
10. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999; 52: 932-937.
11. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001; 57: 1307-1309.
12. Tribl GG, Asenbaum S, Klosch G, et al. Normal IPT and IBZM SPECT in drug naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2002; 59: 649-650.
13. Trenkwalder C, Walters AS, Hening WA, et al. Positron emission tomographic studies in restless legs syndrome. Mov Disord 1999; 14: 141-145.
14. Earley CJ, Kuwabara H, Wong DF, et al. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep 2011; 34: 341-347.
15. Cervenka S, Palhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006; 129: 2017-2028.
16. Walters AS, LeBrocq C, Dhar A, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 2003; 4: 121-132.
17. Park J, Lim S, Lim J, et al. An overview of the Korean Longitudinal Study on Health and Aging (KLoSHA). Psychiatr Invest 2007; 4: 80-91.
18. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4: 101-119.
19. Lee JH, Lee KU, Lee DY, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries. J Gerontol B Psychol Sci Soc Sci 2002; 57: P47-P53.
20. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
21. American Psychiatric Association, American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. Washington, DC: American Psychiatric Association, 1994.
22. Brunswick DJ, Amsterdam JD, Mozley PD, Newberg A. Greater availability of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT imaging. Am J Psychiatry 2003; 160: 1836-1841.
23. Youu S-W, Namkoong K, Kim S-J, et al. Validity of Korean version of the mini-international neuropsychiatric interview. Anxiety Mood 2006; 2: 50-55.
24. Kas A, Payoux P, Habert MO, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. J Nucl Med 2007; 48: 1459-1467.
25. Wetter TC, Eisensehr I, Trenkwalder C. Functional neuroimaging studies in restless legs syndrome. Sleep Med 2004; 5: 401-406.
26. Pittock SJ, Parrett T, Adler CH, Parisi JE, Dickson DW, Ahlskog JE. Neuropathology of primary restless leg syndrome: absence of specific tau- and alpha-synuclein pathology. Mov Disord 2004; 19: 695-699.
27. Earley CJ, Allen RP, Connor JR, Ferrucci L, Troncoso J. The dopaminergic neurons of the A11 system in RLS autopsy brains appear normal. Sleep Med 2009; 10: 1155-1157.
28. Moller JC, Unger M, Stiasny-Kolster K, Oertel WH. Restless Legs Syndrome (RLS) and Parkinson's disease (PD)-related disorders or different entities? J Neurol Sci 2010; 289: 135-137.
29. Jhoo JH, Yoon IY, Kim YK, et al. Availability of brain serotonin transporters in patients with restless legs syndrome. Neurology 2010; 74: 513-518.
30. Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007; 48: 359-366.
31. Garcia-Borreguero D, Williams AM. Dopaminergic augmentation of restless legs syndrome. Sleep Med Rev 2010; 14: 339-346.
32. Schellekens AF, van Oosterwijck AW, Ellenbroek B, et al. The dopamine agonist apomorphine differentially affects cognitive performance in alcohol dependent patients and healthy controls. Eur Neuropsychopharmacol 2009; 19: 68-73. Epub 2008 Oct 2001.
33. Wallace DL, Vytlacil JJ, Nomura EM, Gibbs SE, D'Esposito M. The dopamine agonist bromocriptine differentially affects fronto-striatal functional connectivity during working memory. Front Hum Neurosci 2011; 5: 32.
34. Celle S, Roche F, Peyron R, et al. Lack of specific gray matter alterations in restless legs syndrome in elderly subjects. J Neurol 2010; 257: 344-348.
35. Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 2009; 63: 282-290.